Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Shawn Magee

Pulmonary Disease Topeka, KS Medical Doctor

NPI 1831138460 CMS profile 219311

823 Sw Mulvane St, Topeka, KS 66606

Open in the dashboard

General payments

$645

38 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,303 paid to institutions, not to them · program year 2019

Through program year 2023, Shawn Magee of Topeka, KS is reported in the CMS Open Payments database as having received $645 across 38 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,303 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 36th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $33 1
2022 General $92 1
2020 General $125 8
2019 General $396 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shawn Magee
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Shawn Magee were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Shawn Magee Pulmonary Disease median Middle half National median
2019 $396 $377 $109–$1,340 $163
2020 $125 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $92 $390 $100–$1,457 $149
2023 $33 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Inari Medical, Inc. $92 1 payment
  2. GlaxoSmithKline, LLC. $81 6 payments
  3. AstraZeneca Pharmaceuticals LP $55 3 payments
  4. Jazz Pharmaceuticals Inc. $46 3 payments
  5. Philips Electronics North America Corporation $44 3 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $44 3 payments
  7. Mylan Specialty L.P. $36 3 payments
  8. 3B Medical, Inc. $33 1 payment
  9. Regeneron Healthcare Solutions, Inc. $31 2 payments
  10. Shire North American Group Inc $23 2 payments
  11. Other $161 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $630 37 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2023
  1. FLOWTRIEVER CATHETER, S $92 1 payment
  2. CT THROMBECTOMY SYSTEM KIT $92 1 payment
  3. FASENRA $55 3 payments
  4. NUCALA $47 3 payments
  5. Yupelri $36 3 payments
  6. BREO $35 3 payments
  7. LUNA $33 1 payment
  8. DUPIXENT $31 2 payments
  9. OFEV $29 2 payments
  10. inCourage $27 2 payments
  11. Other $370 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

346

Median for Pulmonary Disease: 936

Drug cost

$340,524

Median for Pulmonary Disease: $487,987

Branded share of claims

79.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xywav Sodium,calcium,mag,pot Oxybate Brand 12 $153,730
Prolastin C Alpha-1-Proteinase Inhibitor Brand 11 $78,354
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 62 $55,521
Breo Ellipta Fluticasone/Vilanterol Brand 36 $17,735
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 34 $16,065
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 13 $7,855
Advair Hfa Fluticasone Propion/Salmeterol Brand 12 $4,893
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 19 $3,598
Albuterol Sulfate Hfa Albuterol Sulfate Brand 76 $2,288
Montelukast Sodium Generic 24 $243

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$166,808

Medicare's payments for the services billed

Medicare patients

793

Average age 74

Services billed

1,689

386 women, 407 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 44%
COPD 43%
Depression 42%
Chronic kidney disease 41%
Diabetes 40%
Heart failure 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record